Table 1 Baseline characteristics of the subjects tested in the present study
Characteristic | Group A (N = 13) | Group B (N = 11) |
|---|---|---|
Age (years) | 56.0 (13.2) | 55.5 (7.8) |
 < 65 | 10 (76.9%) | 9 (81.8%) |
 ≥ 65 | 3 (23.1%) | 2 (18.2%) |
Female sex | 6 (46.2%) | 6 (54.5%) |
Height (m) | 1.642 (0.085) | 1.643 (0.099) |
Weight (kg) | 54.97 (9.16) | 59.15 (14.67) |
Body mass index (kg/m2) | 20.38 (2.85) | 21.67 (3.89) |
Blood pressure (mm Hg) | 128.7 (8.5)/84.7 (13.6) | 118.2 (15.6) / 72.9 (10.0) |
Heart rate (beats/min) | 75.0 (9.3) | 75.6 (8.0) |
Abnormal ECG | 4 (30.8%) | 5 (45.5%) |
Other neurological abnormal findings | 0 (0%) | 0 (0%) |
Muscle CT findings consistent with the target disease | 13 (100%) | 11 (100%) |
Previous diseases | 0 | 0 |
Concurrent diseases | 12 (92.3%) | 9 (81.8%) |
Number of targeted neuromuscular diseases | Â | Â |
 Spinal muscular atrophy | 3 | 2 |
 Spinal bulbar muscular atrophy | 2 | 0 |
 Amyotrophic lateral sclerosis | 1 | 0 |
 Charcot Marie Tooth disease | 1 | 2 |
 Myotonic dystrophy | 0 | 2 |
 Distal myopathy with RV | 0 | 1 |
 Distal myopathy, Myoshi | 2 | 2 |
 FSH-type muscular dystrophy | 2 | 1 |
 Other limb girdle-type muscular dystrophy | 1 | 1 |
 Sporadic inclusion body myositis | 1 | 0 |
 Concomitant treatment, medication | 13 (100%) | 11 (100%) |
 Other rehabilitation programs | 9 (69.2%) | 8 (72.7%) |
 Outpatient during treatment periods | 8 (61.5%) | 2 (18.2%) |
2MWT (metres) | 63.258 (30.457) | 67.257 (25.508) |
Barthel index (total score: 0–100) | 75.4 (21.0) | 84.5 (11.9) |
Total Manual Muscle Test (MMT) scores (0–60) | 31.12 (5.57) | 30.59 (3.64) |